Bausch & Lomb Corp Research and Development in Process
Bausch & Lomb Corp (BLCO) reported Research and Development in Process of $1.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-22
- Bausch & Lomb Corp research and development in process for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Bausch & Lomb Corp research and development in process for the quarter ending 2022-09-30 was $1.00M.
- Bausch & Lomb Corp research and development in process for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Bausch & Lomb Corp research and development in process for the quarter ending 2022-03-31 was $0.00.
- Bausch & Lomb Corp research and development in process for fiscal 2022 was $1.00M, a 80.00% decline from fiscal 2021.
- Bausch & Lomb Corp research and development in process for fiscal 2021 was $5.00M, a 82.14% decline from fiscal 2020.
- Bausch & Lomb Corp research and development in process for fiscal 2020 was $28.00M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.00M derived: sum of 2 quarters · filed 2023-02-22 | $1.00M derived: sum of 3 quarters · filed 2023-02-22 | $1.00M 10-K · filed 2023-02-22 |
| 2022-09-30 | $1.00M 10-Q · filed 2022-11-02 | $1.00M derived: sum of 2 quarters · filed 2022-11-02 | $1.00M 10-Q · filed 2022-11-02 | $5.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $4.00M derived: sum of 3 quarters · filed 2023-02-22 | $4.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2022-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2023-02-22 | $4.00M derived: sum of 2 quarters · filed 2023-02-22 | $4.00M derived: sum of 3 quarters · filed 2023-02-22 | $5.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $4.00M derived: sum of 2 quarters · filed 2023-02-22 | $5.00M derived: sum of 3 quarters · filed 2023-02-22 | $5.00M 10-K · filed 2023-02-22 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | $1.00M derived: sum of 2 quarters · filed 2022-11-02 | $1.00M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-04 | $1.00M 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $28.00M 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| RxSight, Inc. (RXST) | United States | $0.197B | |
| Innovative Eyewear Inc (LUCY) | United States | $0.008B |